In this issue:
Prognostic value of bone marrow MRD status after CAR T cell therapy
Trial enrolment criteria disproportionately exclude racial minorities
Benefit of lenalidomide maintenance according to genetic profile
POMACE: VPd triplet induction efficacious
KarMMa-3: Ide-cel bests standard combos in RR myeloma
Bispecific REGN5459 demonstrates anti-tumour activity in RR disease
TGA COVID-19 vaccine safety report
TGA medicines safety update
TGA makes changes to paracetamol products
Murine myeloma models a step towards precision therapy
Adjunct vedolizumab prevents acute GvHD
Quality of life after CAR T cell therapy
MGUS-like phenotype linked to favourable prognosis
COVID-19 resources
Conferences, Workshops & CPD
Please login below to download this issue (PDF)